Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Melanoma × Thalidomide × Clear all

Phase

Status

Completed 8 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 14 Recurrence 4 Neoplasms, Plasma Cell 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Hepatocellular 4 Colorectal Neoplasms 3 NSCLC 2 Lymphoma, Large B-Cell, Diffuse 2 Esophageal Neoplasms 2 Waldenstrom Macroglobulinemia 1 Stomach Neoplasms 1 Sarcoma 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Neoplasms 1 Melanoma 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Liver Neoplasms 1 Leukemia, Large Granular Lymphocytic 1 Leiomyosarcoma 1 Kidney Neoplasms 1 Immunoglobulin Light-chain Amyloidosis 1 Immunoblastic Lymphadenopathy 1 Glioblastoma 1 Extrapancreatic Neuroendocrine Tumor 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Nivolumab 22 pembrolizumab 16 Ipilimumab 13 Temozolomide 11 toripalimab 9 Biopsy 8 Dacarbazine 7 Blood Specimen Collection 7 Cyclophosphamide 6 trametinib 5 fludarabine 5 dabrafenib 5 camrelizumab 5 atezolizumab 5 durvalumab 4 binimetinib 4 aldesleukin 4 Interleukin-2 4 Injections 4 Gene Expression Profiling 4 Chemotherapy, Adjuvant 4 palbociclib 3 encorafenib 3 apatinib 3 Sorafenib 3 Introns 3 Cisplatin 3 Carboplatin 3 Canvaxin 3 Bevacizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00006200 2005-06-24

Thalidomide and Dacarbazine for Metastatic Melanoma

National Center for Research Resources (NCRR)

Phase 2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡